Third Rock’s Marea ropes in $190M to pioneer ‘the next frontier’ of cardiometabolic medicines

Marea Therapeutics has emerged with $190 million, a mid-stage clinical program and a plan to harness genetics and pioneer “the next frontier” of cardiometabolic medicines.

Marea was incubated by Third Rock Ventures, a healthcare VC that led the San Francisco-based biotech’s series A. The $190 million is the sum of a combined series A and B, with the latter round steered by Sofinnova Investments, and co-led by Forbion, Perceptive Xontogeny Venture Fund and venBio, according to a June 18 release.

The money will be funneled into phase 2 activities for lead program MAR001, a monoclonal antibody (mAb) designed to inhibit ANGPTL4, a protein highly expressed in body fat.

Preclinical models found that MAR001 reduced triglycerides, remnant cholesterol and ectopic fat, while improving insulin sensitivity, according to Marea. The mAb is delivered by subcutaneous injection.

“In a phase 1 trial, a single dose of MAR001 significantly lowered remnant cholesterol levels…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks